Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    50.0%

    Based on 1 completed trials

    Completion Rate
    50%(1/2)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)
    Terminated
    1(50%)

    Phase Distribution

    No phase data available

    Trial Status & Enrollment

    Completion Rate

    50.0%

    1 of 2 finished

    Non-Completion Rate

    50.0%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    2

    all time

    Status Distribution
    Completed(1)
    Terminated(1)

    Detailed Status

    Terminated1
    Completed1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    2
    Active
    0
    Success Rate
    50.0%

    Trials by Status

    terminated150%
    completed150%

    Recent Activity

    0 active trials
    Showing 2 of 2
    completed

    Prevalence of Age Related Macular Degeneration (ARMD) in Parkinson's Patients and Assesment of the Role of L-DOPA

    NCT03415984
    terminated

    Evaluation of the Protective Role of the L-DOPA Against Age Related Macular Degeneration in Parkinson's Patients

    NCT02863640

    Clinical Trials (2)

    Showing 2 of 2 trials
    NCT03415984

    Prevalence of Age Related Macular Degeneration (ARMD) in Parkinson's Patients and Assesment of the Role of L-DOPA

    Completed
    NCT02863640

    Evaluation of the Protective Role of the L-DOPA Against Age Related Macular Degeneration in Parkinson's Patients

    Terminated

    All 2 trials loaded

    Drug Details

    Intervention Type
    Varies by study
    Total Trials
    2